NCT02528994

Withdrawn

Short Term Dietary Serine Supplementation and Circulating Se...

Massachusetts General Hospital Source

Massachusetts General Hospital

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

2014D001170

Study Type

interventional

Actual enrollment (reported)

0

Locations

0 countries

Sites

N/A

Timeline

Study Start

September 2016

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2016

Actual (reported)

Study Completion

September 2016

Actual (reported)

Brief Summary

This study will test the effect of short-term, high-dose dietary serine supplementation on circulating levels of serine. Individuals with risk factors for type 2 diabetes will be recruited into the 2 week study. Effects of dietary serine supplementation on glycemic measures will also be explored.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: September 2016
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
August 18, 2015
Actual (reported)
First Posted
August 19, 2015
Actual (reported)
Study Start
September 2016
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
September 2016
Actual (reported)
Study Completion
September 2016
Actual (reported)

Last Updated: September 16, 2016
Status Verified: September 2016
Last Update Submitted: September 15, 2016

Conditions

Serine

Keywords

Dietary supplementsMetabolism

Outcome Measures

Primary Outcomes (1)

Circulating serine levels
We will measure circulating serine levels after 14 days of intervention
14 days

Secondary Outcomes (2)

Supplement tolerability
14 days
Fasting and post-prandial glucose
14 days

Study Arms (4)

Serine 6g daily

EXPERIMENTAL

Randomized participants will take 6g daily of dietary serine supplement

Dietary Supplement: L-serine

Serine 12g daily

EXPERIMENTAL

Randomized participants will take 12g daily of dietary serine supplement

Dietary Supplement: L-serine

Serine 24g daily

EXPERIMENTAL

Randomized participants will take 24g daily of dietary serine supplement

Dietary Supplement: L-serine

Interventions

L-serineDietary supplement

Participants will take dietary serine supplementation daily

Serine 12g dailySerine 24g dailySerine 48g dailySerine 6g daily

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age20 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

risk factors for type 2 diabetes

You may not qualify if:

Sponsors & Collaborators

Massachusetts General Hospital
Otherlead

MeSH Terms

Interventions

Serine

Intervention Hierarchy (Ancestors)

Amino Acids, NeutralAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

Geoffrey A Walford, MD
Massachusetts General Hospital
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Physician

Study Record Dates

First Submitted

August 18, 2015

First Posted

August 19, 2015

Study Start

September 2016

Date type not reported

This date has not been verified as actual or estimated.

NCT01835782

Determining the Safety of L-serine in ALS

Phase 1/2Unknown

NCT07342439

Study of Serine Supplementation to Protect Vision in MacTel

Phase 3Not Yet Recruiting

NCT06113055

Hereditary Sensory Neuropathy Serine Trial

Phase 2Unknown

NCT07178613

Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs

Phase 1Not Yet Recruiting

NCT07377032

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

Phase 3Recruiting

Serine 48g daily

EXPERIMENTAL

Randomized participants will take 48g daily of dietary serine supplement

Dietary Supplement: L-serine

known type 2 diabetes

women who are pregnant, nursing, or not using contraception or abstinence

taking amino acid supplements during the study or at any time 1 month prior to enrollment in the study

conditions causing intestinal malabsorption, including celiac disease or a history of intestinal or gastric bypass surgery

known active liver disease

currently taking or intending to take during the study duration any medication known to affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones

participation in any other interventional study during the study duration

inability to adhere to study protocol.

Contact the study team to confirm eligibility.

Primary Completion

September 2016

Actual (reported)

Study Completion

September 2016

Actual (reported)

Last Updated

September 16, 2016

Record last verified: 2016-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02528994
Data provider: ClinicalTrials.gov
Source updated: 2016-09-16
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:33 UTC

Study Stopped

Short Term Dietary Serine Supplementation and Circulating Serine Levels

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (4)

Serine 6g daily

Serine 12g daily

Serine 24g daily

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Serine 48g daily

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (4)

Serine 6g daily

Serine 12g daily

Serine 24g daily

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Serine 48g daily

Source record